MEETING MINUTES

SUBJECT: FDA-GPhA Board of Directors (BOD) Quarterly Meeting

DATE: November 19, 2013

FDA ATTENDEES:

Janet Woodcock - Center for Drug Evaluation and Research (CDER)
Robert Guidos - CDER/Office of the Center Director
Kathleen (“Cook”) Uhl - Office of Generic Drug (OGD)
Robert West - OGD
Mary Dempsey - OGD
Jason Woo – OGD
Robert Lionberger - OGD
Keith Flanagan - OGD
Thomas Hinchliffe - OGD
Christina Kirby – OGD
Lawrence Yu – Office of Pharmaceutical Science (OPS)
Mary Beth Clarke - Office of Executive Programs (OEP)
Virginia Behr – CDER Ombudsman
Douglas Stearn - Office of Compliance
Ellen Morrison Office of Regulatory Affairs (ORA)
Theresa Mullin - Office of Strategic Programs (OSP)
Russell Wesdyk - OSP
Manju Thomas - OSP
Katherine Yang - OSP

SPONSOR ATTENDEES:

GPhA Member Company attendees:

Mylan                 Tony Mauro – President
Momenta               Craig Wheeler – President
Zydus                 Joe Renner – President
Ranbaxy               Chuck Caprariello – VP Government Affairs
Teva                  Scott Tomsky – VP US Regulatory Affairs
Impax                 Marcy Macdonald – VP Regulatory Affairs
Perrigo               Richard Stee – VP Regulatory Affairs
Fresenius-Kabi        Molly Rapp – VP Regulatory Affairs
Sandoz                Nicholas Tantillo – VP Regulatory Affairs
Actavis               Beth Brannan – VP Generic Regulatory Affairs
Hospira               Lisa Skeens – SVP Global Regulatory Affairs
Amneal                Candis Edwards – VP Regulatory Affairs
Apotex                Kiran Krishnan – VP Regulatory Affairs

GPhA attendees:

Ralph Neas
David Gaugh
Gordon Johnston
Mark Hendrickson
Agenda (for reference):

I. Introductions

II. Old Business / Action Item Follow Up From Last Meeting:
   A. Easily Correctable Deficiencies  GPhA
      ECD Expectations and Statistics
   B. Pre-CR Major Deficiencies Prior to Complete Response  GPhA
   C. Prioritizing Review Process of ANDAs  FDA
      During the Non-goal Years
   D. Previously Proposed Priority Review System for ANDAs  GPhA

III. New Business
   A. Office of Pharmaceutical Quality (OPQ) Reorganization  FDA
   B. Office of Generic Drugs (OGD) - Policy  FDA
   C. GDUFA Accomplishments and Overview  FDA
   D. GDUFA Industry Responsibilities  GPhA
      Quality of ANDA Submissions

IV. Wrap-up and Next Steps

Topics Discussed/Action Items:

1. GDUFA Goals and commitments were discussed. (slide 5, 6)
2. GPhA’s Easily Correctable Deficiency (ECD) expectations and statistics. (slide 8)
   - GPhA was unable to provide data on industry’s experience with ECDs and feedback on their ability to successfully address deficiencies within 10 business days.
   - GPhA has formed a workgroup consisting of members from the BOD. The workgroup is in a process of creating an ECD document which contains data on their experience thus far on commonly requested ECDs, ECDs the applicant could not respond to in 10 business days and reasons why they were unable to respond within the business 10 days. This document expects to be provided to the FDA in 10 days (November 29, 2013) from this quarterly BOD meeting.
   - GPhA has requested the FDA to assist in data collection. GPhA would like the FDA to monitor and track the percentage of unanswered ECDs along with the reasons given by applicants on why they are unable to respond within the 10 business days.
Action item:

- GPhA: Agreed that they need to complete this and expected to provide a document/paper to FDA 10 days (November 29, 2013) from this quarterly BOD meeting.

- FDA: Begin to collect interim data and statistics on industry’s rationale and reasons for not responding to ECDs within the defined 10 day timeframe.

3. Issuing a subset of Major deficiencies prior to Complete Response. (slide 9)

- GPhA was unable to provide a list of concrete examples representing Pre-CR Major deficiencies.

- GPhA has formed a workgroup similar to above consisting of members from the BOD, and will create and provide a document listing specific examples of what they believe constitutes as Pre-CR Major deficiencies. This document expects to be provided to the FDA in 10 days (November 29, 2013) from this quarterly BOD meeting.

Action item:

- GPhA: Provide a list of concrete examples representing the pre-CR subset of Major deficiencies.

- GPhA/FDA: Keith Flanagan has agreed to facilitate as the point of contact for GPhA to follow up with to produce agreement or paper by end of December.

4. Prioritizing Review Process of ANDAs (during non-goal years) was discussed. (slide 10 and web printout entitled “Activities Report of the Generic Drug Program”)

- FDA to establish internal goals for all cohorts to prioritize non-goal vs. goal year review items.

- FDA Activities report will be updated monthly
  - Report details monthly actions and receipts.

Action item:

- FDA: Break out statistics based on priority cohorts and paragraph filing (paragraph 3, 4, etc.) with details on ins and outs.

- FDA Activities report will be updated monthly and posted on web site: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm375079.htm)
5. Follow up to GPhA proposal for prioritizing review of unapproved ANDAs during the non-goal years. GPhA to re-examine proposal with respect to each applicant providing priority spreadsheets to FDA

- GPhA still working to draft a document to provide clarification on “to whom or where would these lists would be sent” and “what response does the submitter expect to receive from FDA after sending”, will provide in the coming weeks.

- FDA indicated that a quarterly spreadsheet from each applicant detailing their current priority ranking in not feasible. FDA working on priority cohorts that represent fair and unbiased review goals for all industry submissions regardless of GPhA membership.

- FDA would like plan to be apprised in a proactive way of all target patent dates.

**Action item:**

GPhA: Provide a fair, objective, reasonable, unbiased priority proposal it would like to propose/aid FDA in development/refinement of current thinking presented earlier.

6. Office of Pharmaceutical Quality (OPQ) Reorganization overview was detailed by FDA. Additionally, Office of Compliance explained details of a minor reorganization accompanying the OPQ reorganization, specifically reorganizing domestic and international manufacturing compliance divisions to remove the distinction between the two, in recognition of the blending of the two in today's increasingly global supply chain and creating a policy staff that will develop compliance policies for manufacturing quality.

7. Overview of OGD Policy was presented.

- Anticipate to publish key policy documents (MAPPS, Dockets, Guidances): review prioritization, application quality/multiple review cycles issues, amendments (major, minor, delaying, ECD) tiers, dispute resolution, supplement guidance (prior approval, changes being effected, amendments to prior approval, bundling changes, etc.), and controlled correspondences

- Goal is to get these out as soon as possible so they can be finalized before FY15.

8. Overview of current GDUFA accomplishments was discussed. (slide 15-26)

9. GDUFA Industry Responsibilities: *Quality of ANDA Submissions* (slide 27)

The success of GDUFA is a shared responsibility. FDA is hiring, reorganizing, and revamping our processes and procedures to meet the GDUFA mandates. It is incumbent upon industry to improve the quality of its submissions in order for the GDUFA goals to be met. GPhA was tasked at the last quarterly meeting to explore ways to and mechanisms to improve quality of submissions and
present/discuss at next quarterly meeting. GPhA indicated that they are still working on this document which will aide both members and non-members and will provide to FDA upon completion.

FDA reported that ANDA application deficiencies are repetitive. OGD has provided numerous presentations and webinars to industry and the same deficiencies are submitted and resubmitted time and again. GPhA requested beginning a dialogue to address improving the quality of submissions. FDA referred back to the upcoming policy initiative to open a docket with respect to application quality/multiple review cycles issues. It is critical that industry improve efforts to increase the quality of applications to ensure that the GDUFA program is a success.

**Action item:**

GPhA: Develop and provide FDA a document (described as a white paper on “ANDA Completeness and quality of an ANDA Submissions”) that explores ways to and mechanisms to improve quality of submissions.

GPhA: Track the number of 1st cycle Approvals

10. Wrap-up

**Action item:**

FDA: provide activities report updates monthly on publically available website, outline process updates at next meeting, and provide data on P3/P4 and drug shortage

CC:
Janet Woodcock, CDER

David Gaugh, GPhA
## Activities Report of the Generic Drug Program

<table>
<thead>
<tr>
<th>GDUFA Year</th>
<th>10/12</th>
<th>11/12</th>
<th>12/12</th>
<th>1/13</th>
<th>2/13</th>
<th>3/13</th>
<th>4/13</th>
<th>5/13</th>
<th>6/13</th>
<th>7/13</th>
<th>8/13</th>
<th>9/13</th>
<th>Total Yr 1</th>
<th>10/13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actions This Month</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refuse to Receive (RTR)</td>
<td>9</td>
<td>10</td>
<td>4</td>
<td>14</td>
<td>16</td>
<td>15</td>
<td>18</td>
<td>2</td>
<td>17</td>
<td>14</td>
<td>19</td>
<td>20</td>
<td>150</td>
<td>39</td>
</tr>
<tr>
<td>Withdrawals</td>
<td>3</td>
<td>11</td>
<td>10</td>
<td>19</td>
<td>5</td>
<td>3</td>
<td>24</td>
<td>12</td>
<td>4</td>
<td>9</td>
<td>10</td>
<td>6</td>
<td>167</td>
<td>19</td>
</tr>
<tr>
<td>Approvals</td>
<td>25</td>
<td>34</td>
<td>39</td>
<td>29</td>
<td>43</td>
<td>49</td>
<td>41</td>
<td>32</td>
<td>31</td>
<td>45</td>
<td>31</td>
<td>31</td>
<td>440</td>
<td>29</td>
</tr>
<tr>
<td>Tentative Approvals</td>
<td>11</td>
<td>10</td>
<td>4</td>
<td>4</td>
<td>11</td>
<td>6</td>
<td>18</td>
<td>2</td>
<td>11</td>
<td>7</td>
<td>4</td>
<td>9</td>
<td>95</td>
<td>4</td>
</tr>
<tr>
<td>Complete Responses (CR)</td>
<td>126</td>
<td>130</td>
<td>125</td>
<td>97</td>
<td>104</td>
<td>73</td>
<td>104</td>
<td>96</td>
<td>94</td>
<td>92</td>
<td>105</td>
<td>165</td>
<td>1251</td>
<td>113</td>
</tr>
<tr>
<td>Drug Master File Complete Assessment (DMF CA)</td>
<td>18</td>
<td>127</td>
<td>76</td>
<td>189</td>
<td>154</td>
<td>144</td>
<td>147</td>
<td>124</td>
<td>121</td>
<td>178</td>
<td>202</td>
<td>219</td>
<td>1699</td>
<td>181</td>
</tr>
<tr>
<td>Submissions This Month</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abbreviated New Drug Applications (ANDA)</td>
<td>75</td>
<td>56</td>
<td>163</td>
<td>58</td>
<td>51</td>
<td>86</td>
<td>74</td>
<td>46</td>
<td>74</td>
<td>102</td>
<td>83</td>
<td>100</td>
<td>968</td>
<td>41</td>
</tr>
<tr>
<td>Amendments - Originals</td>
<td>183</td>
<td>147</td>
<td>132</td>
<td>176</td>
<td>151</td>
<td>145</td>
<td>183</td>
<td>150</td>
<td>142</td>
<td>146</td>
<td>149</td>
<td>189</td>
<td>1893</td>
<td>176</td>
</tr>
<tr>
<td>To Backlog ANDAs</td>
<td>182</td>
<td>145</td>
<td>127</td>
<td>173</td>
<td>148</td>
<td>137</td>
<td>173</td>
<td>137</td>
<td>129</td>
<td>124</td>
<td>134</td>
<td>162</td>
<td>1771</td>
<td>152</td>
</tr>
<tr>
<td>To Cohort Yr 1 ANDAs</td>
<td>1</td>
<td>2</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>8</td>
<td>10</td>
<td>13</td>
<td>13</td>
<td>22</td>
<td>15</td>
<td>27</td>
<td>122</td>
<td>22</td>
</tr>
<tr>
<td>To Cohort Yr 2 ANDAs</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Amendments - Supplements</td>
<td>171</td>
<td>188</td>
<td>184</td>
<td>176</td>
<td>269</td>
<td>306</td>
<td>232</td>
<td>188</td>
<td>169</td>
<td>163</td>
<td>259</td>
<td>213</td>
<td>2468</td>
<td>216</td>
</tr>
<tr>
<td>To Backlog Prior Approval Supplements (PAS)</td>
<td>38</td>
<td>55</td>
<td>32</td>
<td>37</td>
<td>35</td>
<td>40</td>
<td>39</td>
<td>23</td>
<td>33</td>
<td>34</td>
<td>37</td>
<td>34</td>
<td>437</td>
<td>28</td>
</tr>
<tr>
<td>To Cohort Yr 1 PASs</td>
<td>3</td>
<td>13</td>
<td>41</td>
<td>36</td>
<td>39</td>
<td>56</td>
<td>39</td>
<td>45</td>
<td>22</td>
<td>14</td>
<td>53</td>
<td>54</td>
<td>416</td>
<td>15</td>
</tr>
<tr>
<td>To Cohort Yr 2 PASs</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Tier Amendments</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Tier 1A</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tier 1B</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tier 1C</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tier 2</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Master Files (DMF)</td>
<td>99</td>
<td>63</td>
<td>165</td>
<td>70</td>
<td>71</td>
<td>102</td>
<td>85</td>
<td>64</td>
<td>64</td>
<td>98</td>
<td>72</td>
<td>131</td>
<td>1024</td>
<td>64</td>
</tr>
<tr>
<td>Controls</td>
<td>77</td>
<td>46</td>
<td>56</td>
<td>62</td>
<td>84</td>
<td>74</td>
<td>93</td>
<td>101</td>
<td>106</td>
<td>116</td>
<td>83</td>
<td>56</td>
<td>953</td>
<td>81</td>
</tr>
</tbody>
</table>

### GDUFIA Post CR Meeting Requests

<table>
<thead>
<tr>
<th>STATUS</th>
<th>Number</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancelled</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Denied</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Granted</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Pending</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

| Post CR Meeting Requests This month | 0 | 1 | 0 | 1 | 0 | 4 | 4 | 4 | 2 | 3 | 4 | 23 | 2 |

Page Last Updated: 11/18/2013